Annovis Bio Inc. announced on August 7, 2025, that all of the company’s patents have been successfully transferred from the original form of buntanetap and rewritten to cover the new crystal form. This achievement ensures comprehensive intellectual property (IP) protection for both the original semi-crystalline and the new crystalline forms of buntanetap, extending coverage until 2046. All 13 patent families are filed internationally, securing global coverage.
The company previously identified and characterized a new crystalline form of buntanetap with improved solid-state stability and comparable pharmacokinetic (PK) properties. Animal and human studies demonstrated the bioequivalence of both forms, exhibiting identical systemic exposure. These findings were presented at the Alzheimer’s Association International Conference (AAIC) 2025.
Maria Maccecchini, Ph.D., CEO of Annovis, stated that this is a major milestone for the company, positioning them to continue development and explore buntanetap's therapeutic potential. The new crystal form is currently being used in the pivotal Phase 3 clinical trial in early AD, which was initiated earlier this year and is actively enrolling participants across over 75 sites in the US.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.